Physician profile
Michael Gerardo
NPI 1851588800
$15,132.87
in general payments reported to CMS, 2019-2025
52 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $1,500 · 2021: $2,289 · 2022: $2,143 · 2023: $2,511 · 2024: $3,143 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,924 · Education: $109 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,924.46 |
| Education | $108.89 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,818.09 | 2020-2025 | |
| Lilly USA, LLC | $1,610.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,514.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,185.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,182.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $923.29 | 2019-2025 | Evenity, Prolia, Otezla |
| Otsuka America Pharmaceutical, INC. | $639.37 | 2020-2025 | Rexulti |
| Pfizer INC. | $564.47 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $403.00 | 2019-2025 | Trintellix |
| Allergan, INC. | $363.27 | 2019-2020 | |
| Astellas Pharma US INC | $353.95 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.43 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $259.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $249.24 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $245.85 | 2019-2023 | Belsomra |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gerardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.